Drug intelligence / Profile preview

fH1

Development stage: Phase 1
Lead developer: Sumitomo Pharma
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

fH1 is an antigen component of an adjuvanted universal influenza vaccine (fH1/DSP-0546LP) currently undergoing a first-in-human (FIH) Phase 1 clinical trial. The vaccine aims to assess the safety, tolerability, and immunogenicity of fH1 when administered intramuscularly to healthy adults. It is formulated with the adjuvant DSP-0546LP.

Targets

HA (Hemagglutinin)

Beyond the preview

Go deeper on fH1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on fH1.

Explore the full profile